Biogen/$BIIB
1D1W1MYTD1Y5YMAX
About Biogen
Biogen is an established biopharmaceutical company focused on treatments for neurodegenerative and rare diseases. Its declining multiple sclerosis franchise is its largest revenue generator and contributed 40% of total revenue in 2025. Biogen also generates significant revenue from its CD20 collaboration agreements with Roche (19% of total in 2025), which includes oncology drugs Rituxan and Gazyva and multiple sclerosis drug Ocrevus. Biogen's newer franchises include Spinraza (spinal muscular atrophy, with partner Ionis), Leqembi (Alzheimer's disease, collabroation revenue from its partner Eisai), Skyclarys (Friedreich's ataxia, Reata), Zurzuvae (postpartum depression, Sage), and Qalsody (amyotrophic lateral sclerosis, Ionis).
- Ticker
- $BIIB
- Sector
- Health
- Primary listing
- NASDAQ
- Employees
- 7,500
- Headquarters
- Cambridge, United States
- Website
- www.biogen.com
Biogen Metrics
BasicAdvanced
$31B
37.70
$5.64
0.16
-
Price and volume
Market cap
$31B
Beta
0.16
52-week high
$219.72
52-week low
$131.52
Average daily volume
1.2M
Financial strength
Current ratio
1.865
Quick ratio
0.94
Long term debt to equity
40.084
Total debt to equity
44.329
Interest coverage (TTM)
8.84%
Profitability
EBITDA (TTM)
3,359.2
Gross margin (TTM)
78.32%
Net profit margin (TTM)
8.32%
Operating margin (TTM)
25.09%
Effective tax rate (TTM)
17.48%
Revenue per employee (TTM)
$1,340,000
Management effectiveness
Return on assets (TTM)
5.21%
Return on equity (TTM)
4.58%
Valuation
Price to earnings (TTM)
37.696
Price to revenue (TTM)
3.117
Price to book
1.67
Price to tangible book (TTM)
-18.92
Price to free cash flow (TTM)
12.552
Free cash flow yield (TTM)
7.97%
Free cash flow per share (TTM)
16.933
Growth
Revenue change (TTM)
0.31%
Earnings per share change (TTM)
-46.06%
3-year revenue growth (CAGR)
0.19%
10-year revenue growth (CAGR)
-1.13%
3-year earnings per share growth (CAGR)
-32.52%
10-year earnings per share growth (CAGR)
-10.51%
What the Analysts think about Biogen
Analyst ratings (Buy, Hold, Sell) for Biogen stock.
Biogen Financial Performance
Revenues and expenses
Biogen Earnings Performance
Company profitability
Biogen News
AllArticlesVideos
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real-time US market data is sourced from the IEX order book provided by Polygon. After-hours US market data is 15 minutes delayed and may differ significantly from the actual tradable price at market open.